Comparing Hormonal and Non-Hormonal Treatments

Researchers evaluated changes in the number of sexually satisfying

events, desire, and stress due to frustrating low sexual desire.

• Some pink pills combine herbal extracts like ginseng or maca for effects.
• They are popular in wellness circles for enhancing intimacy and confidence.
• Research on pink pills' long-term safety is limited; caution is advised.
• Available through online stores, pharmacies, or clinics in some regions.

Getting Addyi doesn’t have to be complicated or expensive.

What does this approval mean for other women’s health products?

“Women are now like, ‘I’m gonna demand the care I deserve,’” she says. “The female population is challenging the medical establishment. Medicine’s following their lead, not the other way around.” At the front of that invigorated pack? Cindy, their pink-suited entrepreneurial leader, who’ll never stop talking about a woman’s right to understand that better sex and true desire are part of her overall wellness. Lindsay Geller is the lifestyle director at Women’s Health, where she oversees the Sex & Love, Relationships, and Life sections and manages Women’s Health+ content.

Keys to patient success

She has 10 years of experience covering sex, relationships, health, fitness, and general lifestyle topics for print and digital publications. She currently lives in New Jersey with her husband and loves going on runs around her local park with her rescue dog. WASHINGTON (WLS) -- The Food and Drug Administration has approved the first prescription drug to boost sexual desire in women, nicknamed the "little pink pill." The daily pill, called flibanserin or Addyi, claims to treat low libido in women by working with chemicals in the brain to treat Hypoactive Sexual Desire Disorder, HSDD, which affects approximately one in 10 women. Sprout Pharmaceuticals, maker of the pill, says it will become available on Oct. 17 and will cost between $30 and $75 a month with insurance, on par with Viagra.

Addyi affects

The FDA's approval comes with heavy safety restrictions which will likely prevent Addyi from achieving the blockbuster sales of male impotence drugs like Viagra, which have generated billions of dollars. The new drug's label will carry a bold warning that combining it with alcohol can cause dangerously low blood pressure and fainting. Those problems can also occur if the drug is taken alongside certain common medications, including drugs used to treat yeast infections. The FDA has denied approval for the drug twice since 2010, citing concerns with effectiveness and safety. In June 2015, an FDA advisory panel voted in favor of the drug after hearing emotional testimony. Patients with insurance coverage pay as little as $20 per month2.

Addyi is only $149/month through PHILRx, delivered free to your door, and their coupon is automatically applied.

Find out if treatment is right for you.

In the video below, watch clips from the documentary. In the web extra video below, watch highlights from the FDA’s Dec. 2, 2004 hearing on Procter and Gamble’s Intrinsa, a testosterone patch designed for women. Canner takes issue with framing low sexual desire as a disease or disorder. “I think the problem of putting this in a disease category is it will put pressure on women to perform sexually in a certain way.

How is Addyi supplied (dosage forms)?

It’s not a medical condition in that it’s a sickness or a disease,” Canner said, adding that some medications and conditions do contribute to reduced levels of sexual drive. “There are real reasons why women aren’t desiring their partners anymore—abuse, stress, [and/or] they don’t have a good sex life. This places it on women that there’s something wrong with them, and this can be a real problem and a setback.” What are the side effects of Addyi? The FDA lists dizziness, sleepiness, nausea, fatigue, insomnia and dry mouth as the most common side effects of Addyi. In addition, alcohol is not to be consumed while taking Addyi.

NEED TO KNOW

“I think the really distressing part in all of this is the fact that the FDA approved this drug after rejecting it as an SSRI, and rejected it twice as a treatment for HSDD,” Canner said. “Women may be taking this drug for the rest of their lives, it may affect their babies.” Those may not be the only side effects of Addyi. “Those are the ones we know now,” Chaudhari said. “Sometimes after people begin using medications, we find out about more bad stuff.” Previous FDA rejections and side effects aside, the drug could benefit some women. “I think the biggest reason it wasn’t approved, other than the known side effects, was that it was only a small change in what people call improvement. When brain chemicals fall out of balance, sexual desire can drop too. “Addyi helped me reconnect with my desire in a way that finally felt

Warnings & Precautions

“I don’t think it’s a panacea for the 40 percent of women plagued by this disorder,” she said. “[Patients] would need to understand it’s not a quick fix and it doesn’t help everybody… I would consider prescribing it to the right patient.” Addyi helps balance neurotransmitters like dopamine, serotonin, and norepinephrine to support sexual desire. The exact way Addyi works is unknown. ADDYI was studied in four 6-month clinical trials in more than 3,200 women with low sexual desire, of whom 902 were postmenopausal and under 65. Participants were randomly assigned to receive ADDYI or a placebo. sustainable.” “After menopause, I thought losing desire was just something I had to accept.

if she’s saying these things, it may be hsdd

On an individual basis, it could be big. But in a study it’s difficult to prove,” Chaudhari said. “It doesn’t mean it won’t help someone. I think it wasn’t approved [before] because it’s difficult to show improvement and this [time around] showed some. It doesn’t seem like a lot but to a woman affected by it, it may be enough for her to take on the side effects and the risks.” That said, Chaudhari says the drug should not be looked to as a panacea and she would prescribe it to select patients. Addyi helped me realize I didn’t.” “For the first time in

• The pink pill targets issues like low desire and menstrual discomfort.
• It may improve mood and increase energy levels in women.
• Side effects can include headaches, nausea, or hormonal imbalances.
• Its use is often personalized based on hormonal levels and health status.

a long time, I feel more engaged and satisfied during sex,

The Big Pink Fight for the Little Pink Pill

Patients should discontinue treatment after eight weeks if they do not report an improvement in sexual desire and associated distress.” Chaudhari says, “Looking at the mechanism of the drug is really interesting because we don’t totally understand how sexual response works in women.” That’s because sexual response in women is multifactorial. “Women are affected by chemical levels in the brain, and we think when we have high levels of one chemical, perhaps we can have a decrease in sexual desire versus other chemicals that might improve sexual desire,” she said. In addition, external factors such as mood and relationship issues can affect a woman’s sexual desire. “This is why it makes it so difficult; research around this topic is so limited,” she said. “Studies on women are more difficult because we don’t totally understand women’s sexual response.” “Viagra is just used for men with erectile dysfunction, and it supposed to be used immediately before intercourse to maintain an erection,” Chaudhari said.

More common

“[Addyi] is meant to be a maintenance medication for women. “It’s not something you can pop before intercourse and be in the mood to have intercourse,” she added. “You have to take it every day in a long-term format.” Liz Canner is the director of Orgasm Inc., a documentary about the pharmaceutical industry’s race to create a female version of Viagra. Canner began working for a pharmaceutical company editing erotic videos to be used for a drug trial. She simultaneously began filming an independent documentary about science and women’s pleasure.

Liver impairment

During filming, she said she discovered that the pharmaceutical company seemed more interested in making cenforce d 160 a profit than helping women. “I remember asking things like why start working on a drug, and no one wanted to tell me that. What are the characteristics of this disease, and they’d say, ‘We don’t know really.’ It seemed very fuzzy. I don’t think there’s anything wrong with developing creams for pleasure if it doesn’t harm,” she said. “[Viagra] worked on men with erectile dysfunction [and] they thought this would be a bigger movement [that could work on women]. not distracted or checked out.” “I had no desire, I thought it was just me… something that happened as I got older.

i don’t have sexual thoughts anymore

The Associated Press contributed to this report. In the headlines it's often called female Viagra, but medical experts say it should not at all be compared to the erectile dysfunction drug. The female version will become available in October and carries the brand name, Addyi. In June, it became the first Food and Drug Administration-approved drug to treat what's clinically called hypoactive sexual desire disorder in women. But the pink-tinted pill was resoundingly rejected twice before by the FDA and Addyi continues to have more than its share of detractors.

Is Lack of Desire all in Our Heads??

While the drug maker, Sprout Pharmaceuticals, says clinical trials showed it to improve women's libido, critics say the pill carries too many potential risks and questions still abound over whether female sexual dysfunction can be treated with medication. Joining Chicago Tonight to discuss the pill are Dr. Stacy Tessler Lindau, associate professor of obstetrics/gynecology and medicine-geriatrics at the University of Chicago Medical School; Dr. Jessica Shepherd, University of Illinois College of Medicine at Chicago; Alessandra Hirsch, a project consultant with PharmedOut, a Georgetown University Medical Center project; and Carl Jenkins, an FDA regulatory lawyer at the Wood Burditt Group. Addyi is the brand name of flibanserin, which was approved earlier this month by the FDA to “treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women,” according to an FDA press release.

As Seen In

“It’s basically decreased interest in sexual activity or desire, which is a very common problem for premenopausal and postmenopausal women,” Dr. Angela Chaudhari, a Northwestern Medicine gynecologist explained. “I think it affects 40 percent of premenopausal women and 60 percent of postmenopausal women. Unfortunately, it’s a big problem in the country and it’s not frequently addressed.” “Addyi is a serotonin 1A receptor agonist and a serotonin 2A receptor antagonist, but the mechanism by which the drug improves sexual desire and related distress is not known. It is dosed at bedtime to help decrease the risk of adverse events occurring due to possible hypotension, syncope and central nervous system depression (such as sleepiness and sedation).